Bozec Aline, Ruffion Alain, Decaussin Myriam, Andre Jean, Devonec Marian, Benahmed Mohamed, Mauduit Claire
Institut National de la Santé et de la Recherche Médicale U 407, Faculté de Médecine Lyon-Sud, BP 12, 69921 Oullins Cedex, France.
J Clin Endocrinol Metab. 2005 Jan;90(1):17-25. doi: 10.1210/jcem.90.8.9993. Epub 2004 Oct 26.
Benign prostatic hyperplasia (BPH) results from an increase in both epithelial and stromal compartments of the human prostate. Although inhibitors of 5alpha-reductase such as finasteride have been shown to reduce the size of BPH tissues by inducing apoptosis, their mechanisms of action still remain unknown. The present study supports that such a process triggered by finasteride is caspase dependent with a possible involvement of two effector caspases (caspase-3 and 6) and two initiator caspases (caspase-8 and 9). Indeed, by using tissues from patients affected by BPH and treated by finasteride (5 mg/d) for 2-3, 6-8, or 27-32 d, we observed that the 5alpha-reductase inhibitor induced apoptosis in epithelial cells (evaluated through cell number positive for terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) as early as 2-3 d of treatment, with a maximal activity (250-fold increase, P < 0.0001) at 6-8 d of treatment. However, after 27-32 d of treatment, the number of apoptotic cells was reduced and was close to control. Caspases-3, -6, -8, and -9 were immunolocalized to (basal and secretory) epithelial cells and to a lesser extent to stromal cells. Activated caspase-3 immunoexpression was restricted to epithelial secretory cells, and its immunostaining intensity appeared to be higher in BPH tissues from patients treated for 2-3 or 6-8 d. Consistently, in Western blotting analyses, activated caspases-3 and -6 were detected as early as 2-3 d of treatment in BPH tissues, and their levels were increased after 6-8 d of treatment. In real time quantitative PCR experiments, caspase-3 and -6 mRNA levels were found to be unchanged after finasteride treatment. Activated caspase-8 was not detected in the different conditions tested, whereas activated caspase-9 protein levels were maximally enhanced after 2-3 d of finasteride treatment. In conclusion, we report here that finasteride treatment of BPH tissues induced a caspase-dependent apoptotic process restricted to epithelial cells by activating effector caspases-3 and -6 and exhibited a transient action because the apoptotic process was no longer observed after 27-32 d of treatment.
良性前列腺增生(BPH)是由人类前列腺上皮和基质成分均增加所致。尽管非那雄胺等5α-还原酶抑制剂已被证明可通过诱导细胞凋亡来减小BPH组织的大小,但其作用机制仍不清楚。本研究支持非那雄胺引发的这一过程是半胱天冬酶依赖性的,可能涉及两种效应半胱天冬酶(半胱天冬酶-3和6)和两种起始半胱天冬酶(半胱天冬酶-8和9)。实际上,通过使用受BPH影响并接受非那雄胺(5毫克/天)治疗2 - 3天、6 - 8天或27 - 32天的患者的组织,我们观察到5α-还原酶抑制剂早在治疗2 - 3天时就诱导上皮细胞凋亡(通过末端脱氧核苷酸转移酶介导的脱氧尿苷三磷酸缺口末端标记阳性细胞数评估),在治疗6 - 8天时活性达到最大(增加250倍,P < 0.0001)。然而,在治疗27 - 32天后,凋亡细胞数量减少并接近对照组。半胱天冬酶-3、-6、-8和-9免疫定位于(基底和分泌)上皮细胞,在基质细胞中的定位程度较低。活化的半胱天冬酶-3免疫表达局限于上皮分泌细胞,其免疫染色强度在接受2 - 3天或6 - 8天治疗的患者的BPH组织中似乎更高。同样,在蛋白质印迹分析中,早在治疗2 - 3天时就在BPH组织中检测到活化的半胱天冬酶-3和-6,其水平在治疗6 - 8天后升高。在实时定量PCR实验中,发现非那雄胺治疗后半胱天冬酶-3和-6的mRNA水平未发生变化。在测试的不同条件下未检测到活化的半胱天冬酶-8,而活化的半胱天冬酶-9蛋白水平在非那雄胺治疗2 - 3天后最大程度增强。总之,我们在此报告,非那雄胺治疗BPH组织通过激活效应半胱天冬酶-